- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.10. | Chutes & Ladders-Less than a year in, BenevolentAI CEO is out | 16 | FierceBiotech | ||
| 18.10. | BenevolentAI CEO steps down as founders make a comeback | 12 | pharmaphorum | ||
| BENEVOLENTAI Aktie jetzt für 0€ handeln | |||||
| 17.10. | BenevolentAI Appoints Kenneth Mulvany as Executive Chairman | 189 | Business Wire | Founder of leading AI drug discovery company returns to the executive management team to capitalise on the growing adoption of AI in drug discovery and development
BenevolentAI ("BenevolentAI"... ► Artikel lesen | |
| 10.10. | BenevolentAI to Present on Explainable AI for Drug Discovery at BioTechX Europe 2024 | 226 | Business Wire | BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that Dr James Malone, Chief Technology... ► Artikel lesen | |
| 19.09. | BenevolentAI Interim Results for the Six Months Ended 30 June 2024 | 317 | Business Wire | Strengthened Executive Leadership and Board Positive Top Line Phase I Data Reported for BEN-8744, Full Data to be Presented at Upcoming Leading Medical Conference Advancements in Target Identification... ► Artikel lesen | |
| 06.09. | BenevolentAI Notice of Interim Results | 296 | Business Wire | BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, will announce its interim results for the six months... ► Artikel lesen | |
| 04.07. | BenevolentAI: Appointment of Adviser | 307 | Business Wire | BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the... ► Artikel lesen | |
| 03.07. | BenevolentAI: Leadership Team Change | 308 | Business Wire | Regulatory News:
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced artificial intelligence (AI) to accelerate biopharma drug discovery, today... ► Artikel lesen | |
| 25.06. | AstraZeneca adds novel systemic lupus erythematosus target with BenevolentAI | 3 | Seeking Alpha | ||
| 25.06. | BenevolentAI and AstraZeneca Collaboration Yields Continued Success as Further Novel Target Progressed Into Portfolio | 724 | Business Wire | BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that AstraZeneca has added a novel target... ► Artikel lesen | |
| 19.06. | BenevolentAI CEO to Join Panel at Morgan Stanley 3rd Annual Life Sciences AI Summit | 315 | Business Wire | BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces that it will participate in the upcoming... ► Artikel lesen | |
| 04.06. | BenevolentAI to participate in Goldman Sachs 45th Annual Global Healthcare Conference | 291 | Business Wire | BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that it will participate in the upcoming... ► Artikel lesen | |
| 15.05. | BenevolentAI Announces Further Success With AstraZeneca Collaboration as Novel Heart Failure Target Selected | 650 | Business Wire | BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that AstraZeneca has added a novel target... ► Artikel lesen | |
| 02.05. | BenevolentAI: Result of Annual General Meeting | 275 | Business Wire | Regulatory News:
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery announces that all resolutions... ► Artikel lesen | |
| 23.04. | BenevolentAI Provides an Update on Its Business Priorities | 466 | Business Wire | Regulatory News:
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces an update on... ► Artikel lesen | |
| 17.04. | BenevolentAI: Publication of the Revised Agenda for the 2024 AGM | 432 | Business Wire | Regulatory News:
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces the publication... ► Artikel lesen | |
| 15.04. | Proposed Changes to BenevolentAI's Board Composition | 427 | Business Wire | Regulatory News:
BenevolentAI (or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces that following extensive discussions... ► Artikel lesen | |
| 25.03. | BenevolentAI Announces Positive Topline Safety and Pharmacokinetic Data from the Phase Ia Clinical Study of BEN-8744 in Healthy Volunteers | 352 | Business Wire | Regulatory News:
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces positive safety... ► Artikel lesen | |
| 20.03. | BenevolentAI: Publication of 2023 Annual Report and 2024 AGM Notice | 325 | Business Wire | Regulatory News:
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces the publication... ► Artikel lesen | |
| 20.03. | BenevolentAI Appoints New Chief Technology Officer | 534 | Business Wire | BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces that the current Chief Technology... ► Artikel lesen |
Seite:
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ABCELLERA BIOLOGICS | 2,879 | -0,42 % | AbCellera Reports Q2 2024 Business Results | VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced financial results for the second quarter of 2024. All financial information in this press release is reported... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,335 | -3,17 % | Recursion Pharmaceuticals, Inc.: Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma | First program to result from end-to-end use of OS to identify a novel target and new chemical matter, which moved from target ID to IND enabling studies in under 18 months with ~200 compounds synthesizedREC-1245... ► Artikel lesen | |
| VERACYTE | 40,800 | -2,86 % | Finanzvorstand von Veracyte verkauft Aktien im Wert von 215.833 US-Dollar | ||
| ASCLETIS PHARMA | 0,173 | 0,00 % | ASCLETIS-B (01672): NEXT DAY DISCLOSURE RETURN | ||
| RELAY THERAPEUTICS | 4,485 | -3,65 % | Relay Therapeutics, Inc.: Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors | Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008)Lirafugratinib is a potential best-in-class FGFR2 inhibitor that has shown... ► Artikel lesen | |
| ABSCI | 2,995 | -5,22 % | Absci Corporation: Absci Reports Business Updates and Third Quarter 2024 Financial and Operating Results | Successfully delivered AI de novo designed antibody sequences to AstraZeneca, fulfilling first milestone under collaboration Entered into collaboration with Twist Bioscience to design a novel antibody... ► Artikel lesen | |
| LANTERN PHARMA | 3,350 | +5,35 % | Lantern Pharma rises on FDA 'fast track' tag for breast cancer drug | ||
| QIAGEN | 41,475 | -0,48 % | QIAGEN N.V.: QIAGEN führt neuartige Tools zur Anpassung von digitalen PCR-Assays und NGS-Panels für die mikrobielle Analyse ein | QIAGEN führt das erste Design-Tool für individuell anpassbare digitale PCR-Assays im Markt ein, ausgestattet mit fortschrittlichen Design-Algorithmen für verschiedene mikrobielle Anwendungen und kundenspezifische... ► Artikel lesen | |
| EVOTEC | 8,585 | -3,86 % | wO Börsenlounge: Amazon | Hugo Boss | Evotec - nach Chipotle explodiert ein ganz neuer Wert! | Die Erfolgsgeschichte von Chipotle Mexican Grill ist zuletzt etwas ins Stocken geraten. Dafür springt ein neuer Wert in die Bresche. Seit Jahresanfang legt die Aktie um 200 Prozent zu und das dürfte... ► Artikel lesen | |
| JANUX THERAPEUTICS | 62,97 | +56,88 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
| BIONTECH | 111,20 | -0,36 % | Evotec, Vidac Pharma, BioNTech - Krebsforschung: Die Goldgrube im Depot | Investitionen in Aktiengesellschaften, die im Bereich der Onkologieforschung tätig sind, bieten vielversprechende Renditechancen und langfristige Stabilität. Der Onkologiemarkt gehört zu den wachstumsstärksten... ► Artikel lesen | |
| CITIUS ONCOLOGY | 1,510 | +48,04 % | Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA) and LYMPHIR in Cancer Patients ... | Study, in patients with solid tumors focusing on gynecological malignant tumors such as ovarian, endometrial, and cervical, nearing completion with three remaining subjects to be enrolled27%... ► Artikel lesen | |
| VERVE THERAPEUTICS | 7,320 | +2,59 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on November 29,... ► Artikel lesen | |
| ADMA BIOLOGICS | 19,870 | +0,91 % | Biotech Leader ADMA Hits New Buy Point After Recovering From Surprise Plunge | ||
| GUBRA | 91,80 | -5,94 % | AKTIONÄR-Depotwert Gubra: Nächstes Kaufsignal - neue Rekorde in Sicht | Die Bullen bleiben beim AKTIONÄR-Depotwert Gubra am Drücker. Zum Start in die neue Handelswoche strebt die Aktie des dänischen Wirkstoffforschers an der Heimatbörse in Kopenhagen auf ein neues Verlaufshoch... ► Artikel lesen |
BENEVOLENTAI gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,696 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BENEVOLENTAI finden Sie auf Wallstreet Online.
